
    
      This clinical trial aims to demonstrate the safety of the Closed-Loop Control (CLC), also
      known as Artificial Pancreas (AP) named t:slim X2 with Control-IQ Technology and assess
      usability in a supervised setting for the treatment of type 1 diabetes (T1D) in young
      children (2-6 years old).
    
  